((自动化翻译由路透提供，请见免责声明 ))
10月10日 - ** 药物开发商 Lipocine 的股票在盘前交易中上涨 6.19%，收于 5.5 美元
** 该公司用于治疗产后抑郁症的口服brexanolone (link) 与有效控制抑郁、焦虑、震颤和癫痫发作的疗法一致
**在第一阶段研究中，口服 brexanolone 的耐受性良好，其安全性与以前的临床研究一致。
** 截至上一交易日收盘，股价累计上涨 85.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.